An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management

Decker, Paul A.; Moulinet, T.; Pontille, Fabien; Cravat, Maxime; Bittencourt, Marcelo De Carvalho; Jaussaud, R.

doi:10.1016/j.autrev.2021.103013

Cited by 29 publications

(26 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aunque otros tampoco lograron encontrar asociaciones clínicas, 7 se han descrito anticuerpos anti-Ro52/TRIM21 en bloqueo cardiaco congénito, lupus neonatal, enfermedad valvular, miopatía inflamatoria y enfermedad pulmonar intersticial, lo que sugiere que los anticuerpos anti-Ro52/TRIM21 sí están asociados a reacciones autoinmunes. [27][28][29][30][31] Además, queda por definir si la asociación entre anticuerpos anti-Ro52/TRIM21 y la respuesta inmune anormal es un proceso estático en el que la mera presencia de anticuerpos condiciona una producción aberrante de citocinas o, por el contrario, si es un fenómeno dinámico donde estos últimos fluctúan continuamente en relación con la actividad de la enfermedad, el funcionamiento de otros anticuerpos, el sustrato genético y otros factores no directamente relacionados con la autorreactividad contra la molécula TRIM21.…”

Section: Figura 5 Redes De Interacción Proteína-proteína Con Análisis...unclassified

Los anticuerpos anti-Ro52/TRIM21 están asociados a circuitos inflamatorios aberrantes en pacientes con enfermedades reumáticas autoinmunes sistémicas

Amezcua-Guerra¹,

Pérez-García²,

Jiménez-Rojas³

et al. 2023

GMM

View full text Add to dashboard Cite

Introducción: Los anticuerpos anti-Ro52/TRIM21 son marcadores de varias enfermedades reumáticas autoinmunes sistémicas (ERAS). Objetivo: Evaluar si los anticuerpos anti-Ro52/TRIM21 están relacionados con anomalías en los circuitos inflamatorios. Métodos: Estudio transversal de pacientes consecutivos y ambulatorios con ERAS. Los anticuerpos anti-Ro52/ TRIM21 y la proteína amiloide sérica se midieron mediante ELISA; los paneles para 18 citocinas y nueve quimiocinas se analizaron en una plataforma de lectura Luminex; la proteína C reactiva (hs-CRP) y el complemento se midieron mediante nefelometría. Resultados: Se incluyeron 167 pacientes, 143 con lupus eritematoso sistémico (LES), 16 con síndrome de Sjögren primario y ocho con esclerosis sistémica; 41 fueron positivos para anticuerpos anti-Ro52/TRIM21 (24 %). Los pacientes con anticuerpos anti-Ro52/TRIM21 tuvieron niveles séricos más altos de IL-2, IL-4, IL-6, GM-CSF, IL-21, IL-22, hs-CRP y quimiocinas CCL4, CXCL8, CXCL10 y CXCL12; y más bajos de complemento C4. Los títulos de anticuerpos anti-Ro52/TRIM21 correlacionaron positivamente con IL-2, IL-4, IL-6, IL-10, IL-21, IL-22, CXCL10 y hs-CRP; y negativamente con complemento C3 y C4. Al incluir solo LES, no se identificó asociación entre los anticuerpos anti-Ro52/TRIM21 y la actividad de la enfermedad o la afectación específica de órganos. Conclusiones: Los anticuerpos anti-Ro52/TRIM21 se asocian a circuitos aberrantes de citocinas y niveles elevados de moléculas angiogénicas y quimioatrayentes de neutrófilos y monocitos, lo que sugiere un papel activo de esos anticuerpos en las ERAS.

show abstract

Section: Figura 5 Redes De Interacción Proteína-proteína Con Análisis...unclassified

Los anticuerpos anti-Ro52/TRIM21 están asociados a circuitos inflamatorios aberrantes en pacientes con enfermedades reumáticas autoinmunes sistémicas

Amezcua-Guerra¹,

Pérez-García²,

Jiménez-Rojas³

et al. 2023

GMM

View full text Add to dashboard Cite

show abstract

“…Aside from the aberrant activation and proliferation of the B-cell, anti-Ro (SSA), and anti-La (SSB) auto-antibodies, which are a hallmark of SS, the short cytoplasmic RNP-bound peptides SSA-60kD, SSA-52kD, and SSB-48kD are too. However, studies suggest that the direct effects of anti-Ro52 auto-antibodies can cause glandular dysfunction in the SS group [ 178 ]. Indeed, abundant evidence implies that different immune components are active at various phases, that is, the condition is characterized by the aberrant mucus production caused by proinflammatory mediators [ 179 , 180 ] or the inflammatory edema of the conjunctiva via the activation of P2X7 [ 181 , 182 ].…”

Section: Mucus Abnormalities and Diseasementioning

confidence: 99%

View from the Biological Property: Insight into the Functional Diversity and Complexity of the Gut Mucus

Gao

Xin

et al. 2023

IJMS

View full text Add to dashboard Cite

Due to mucin’s important protective effect on epithelial tissue, it has garnered extensive attention. The role played by mucus in the digestive tract is undeniable. On the one hand, mucus forms “biofilm” structures that insulate harmful substances from direct contact with epithelial cells. On the other hand, a variety of immune molecules in mucus play a crucial role in the immune regulation of the digestive tract. Due to the enormous number of microorganisms in the gut, the biological properties of mucus and its protective actions are more complicated. Numerous pieces of research have hinted that the aberrant expression of intestinal mucus is closely related to impaired intestinal function. Therefore, this purposeful review aims to provide the highlights of the biological characteristics and functional categorization of mucus synthesis and secretion. In addition, we highlight a variety of the regulatory factors for mucus. Most importantly, we also summarize some of the changes and possible molecular mechanisms of mucus during certain disease processes. All these are beneficial to clinical practice, diagnosis, and treatment and can provide some potential theoretical bases. Admittedly, there are still some deficiencies or contradictory results in the current research on mucus, but none of this diminishes the importance of mucus in protective impacts.

show abstract

“…Moreover, antithyroid antibody was suggested to be associated with thyroid dysfunction after ICIs treatment ( 6 ). Anti-Ro52 (TRIM21) antibody, one member of the ANA profile, is regarded to be associated with many autoimmune diseases, especially Sjogren’s syndrome, systemic lupus erythematosus, and systemic sclerosis ( 10 ). The prevalence of anti-Ro52 antibody varies in malignant diseases ( 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

Tang

Geng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.MethodsThe present retrospective cohort study evaluated the safety and efficacy of PD-1/PD-L1 inhibitors in patients with preexisting autoantibodies. Patients who received PD-1/PD-L1 inhibitors in the Department of Medical Oncology, Peking Union Medical College Hospital between November 2017 and August 2021 were reviewed.Results67 (37.9%) of the 177 patients, 27 (20.3%) of the 133 patients, and 16 (11.0%) of 146 patients who received PD-1/PD-L1 inhibitors were positive for ANA, anti-Ro52, and antithyroid antibodies, respectively. Preexisting ANA and anti-Ro52 antibody were not associated with the increased risk of immune-related adverse events (irAEs), while thyroid dysfunction was more frequent in patients with positive antithyroid antibody (75.0% versus 13.8%, p < 0.001). The median progression-free survival (PFS, 13.1 versus 7.0 months, p = 0.015) was significantly longer in the ANA-positive patients, while the median overall survival (OS, 14.5 versus 21.8 months, p = 0.67) did not differ significantly between the ANA-positive and ANA-negative groups. Moreover, the preexisting anti-Ro52 and antithyroid antibodies were not significantly associated with PFS and OS.ConclusionsThe presence of ANA and anti-Ro52 antibody were not associated with a higher risk of irAEs, whereas patients positive for antithyroid antibody should monitor closely immune-related thyroid dysfunction. Preexisting ANA might be a predictor of longer PFS, while anti-Ro52 and antithyroid antibodies had no significant effect on survival outcomes in patients receiving PD-1/PD-L1 inhibitors therapy.

show abstract

An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management

Cited by 29 publications

References 84 publications

Los anticuerpos anti-Ro52/TRIM21 están asociados a circuitos inflamatorios aberrantes en pacientes con enfermedades reumáticas autoinmunes sistémicas

Los anticuerpos anti-Ro52/TRIM21 están asociados a circuitos inflamatorios aberrantes en pacientes con enfermedades reumáticas autoinmunes sistémicas

View from the Biological Property: Insight into the Functional Diversity and Complexity of the Gut Mucus

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

Contact Info

Product

Resources

About